BioStock: CombiGene’s CEO on the participation at BIO2023 in Boston

At the beginning of 2023, CombiGene’s CEO Jan Nilsson and Zyneyro’s CEO Peter Horn Møller signed a collaboration agreement for the development of new therapies for the treatment of severe chronic pain conditions. Both CEOs have just returned from the world’s largest biotech conference, BIO2023 in Boston. BioStock talked to Jan Nilsson about the purpose of their participation.

Read the full interview with Jan Nilsson at biostock.se:

https://www.biostock.se/en/2023/06/combigenes-ceo-on-the-participation-at-bio2023-in-boston/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/